Bone Mass Analysis
Bone Mass Analysis - Related Videos
10:23
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
0 Views •
Cited by 7 •
2017
Lipid droplets are important organelles for the replication of several pathogens, including the Hepatitis C Virus (HCV). We describe a method to isolate lipid droplets for quantitative mass spectrometry of associated proteins; it can be used under a variety of conditions, such as virus infection, environmental stress, or drug treatment.
08:09
Preparation of Whole Bone Marrow for Mass Cytometry Analysis of Neutrophil-lineage Cells
0 Views •
Cited by 14 •
2019
Here, we present a protocol to process fresh bone marrow (BM) isolated from mouse or human for high-dimensional mass cytometry (Cytometry by Time-Of-Flight, CyTOF) analysis of neutrophil-lineage cells.
07:29
Undecalcified Bone Preparation for Histology, Histomorphometry and Fluorochrome Analysis
0 Views •
Cited by 32 •
2010
Undecalcified bone histology provides important information for a variety of clinical and research applications. It is technically challenging, particularly with large size specimens. This video illustrates the process of producing good quality sections and demonstrates the technical difficulties and methods with which to overcome them.
13:09
Mass Spectrometric Analysis of Glycosphingolipid Antigens
0 Views •
Cited by 9 •
2013
A specific and sensitive method to gain insight into the expression profile of glycosphingolipid antigens in immune organs and cells is described. The method takes advantage of the ion trap mass spectrometry allowing step-wise fragmentation of glycosphingolipid molecules for structural analysis in comparison to chemically synthesized standards.
08:49
Models of Bone Metastasis
0 Views •
Cited by 115 •
2012
Animal models are frequently utilized to study cancer metastasis to bone. In this protocol we will describe two common methods of tumor inoculation for bone metastasis studies and briefly describe some of the analyses utilized to monitor and quantify these models.
FAQs
DXA uses two low-dose X-ray beams because their differing attenuation by bone provides the basis for software estimation. The resulting measurement is not simply a visual image: the system converts the X-ray behavior into quantitative values, particularly areal bone mineral density. This mechanism supports standardized comparison with reference populations.
Bone mineral content and areal bone mineral density describe related but distinct outputs. Content represents the measured mineral amount, whereas density expresses mineral content in relation to the scanned area. Considering the density result is clinically important because it provides an indicator associated with skeletal strength and fracture risk, while content adds complementary quantitative information.
Changes in bone mass can be examined across several medical contexts, including skeletal development, aging, metabolic bone disorders, medication effects, and lifestyle interventions. These contexts matter because a measurement can be used not only to identify low bone density but also to evaluate whether skeletal characteristics or an intervention-associated pattern changes over time.
A DXA-based workflow begins by exposing the relevant skeletal measurement area to two low-dose X-ray beams. Software then estimates areal bone mineral density from the beams' attenuation and compares the result with reference populations. The essential output is therefore a quantitative, software-derived assessment rather than a judgment based only on symptoms or visual inspection.
Clinicians use results in several linked decisions: recognizing low bone density, supporting an osteoporosis diagnosis, monitoring changes during treatment, and guiding fracture-prevention strategies. The measurement supplies quantitative skeletal information that can inform these clinical decisions and help track the relationship between bone status and ongoing care.
In research, Bone Mass Analysis provides a way to evaluate skeletal outcomes across development and aging, investigate metabolic bone disorders, and examine effects associated with medications or lifestyle interventions. In medicine, the same quantitative framework links measurement with fracture-risk assessment and treatment monitoring, allowing studies and clinical practice to address both bone status and change.